ClinicalTrials.gg
CompletedNCT04250363Updated May 1, 2024Results posted

Chemoprophylactic Activity of M5717 in PfSPZ Challenge Model

A Phase 1 interventional study of PfSPZ Challenge and Palcebo in Healthy, sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-01.

Sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 24 studies in Malaria with a site in Netherlands — none open to participants now, none under way, none of them phase 3. Malaria · Netherlands.

Enrollment
6th of 23
39 · median 25
Started
2020
with 1 other
Phase 1
7 of 24
none open now
Registered
22nd of 24
by date
Lead sponsor
1 of 24
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Among the 24 studies in Malaria with a site in Netherlands, this one is the 6th largest by enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2020, is one of 7 in phase 1, and was the 22nd registered.

Malaria

1,187 studies on the registry are indexed under Malaria; 80 are open to participants now.

Browse Malaria studies →

Open to participants now

None of the 24 studies in Malaria with a site in Netherlands is open now. The open studies under Malaria, anywhere →

Who these studies take

Of the 51 Malaria studies recruiting now, 15 (29%) set no upper age limit and 33 (65%) stop at 75 or younger; 37 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies in Malaria with a site in Netherlands as a file.
02

Study summary

The main purpose of this study was to assess the chemoprophylactic activity and dose-exposure-response relationship of single oral dose of M5717 administered after direct intravenous inoculation (DVI) of Plasmodium falciparum sporozoite (PfSPZ) challenge in healthy participants.

03

Conditions studied

  • Healthy

Keywords

  • Healthy Participants
  • M5717
  • Malaria
  • Plasmodium falciparum
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are overtly healthy as determined by medical evaluation, including no abnormality identified on physical examination or laboratory evaluation and no active clinically significant disorder, condition, infection or disease that would pose a risk to participant safety or interfere with the study evaluation, procedures or completion
  • Participants who have a body weight within 50 to 100 kilograms (kg) and within the range 19.0 to 29.9 kilograms per meter square (kg/m2) (inclusive)
  • Male participants, during the study intervention period and for at least 120 days after the day of the study intervention dose (covering a full sperm cycle of 90 days starting after 5 half lives of last dose of study intervention: - refrain from donating sperm plus, either - abstain from intercourse with a woman of (WOCBP) or - use a male condom, when having sexual intercourse with a WOCBP, who is not currently pregnant, and advise her to use a highly effective method with a failure rate of less than (\<) 1 percent (%) per year, since a condom may break or leak
  • Female participants who are: - not a WOCBP; - at least 1 year (amenorrhea greater than or equal to [>=] 12 months and follicle-stimulating hormone [FSH] >= 40 milli-international units per milliliter [mIU/mL]) at screening; - surgically sterile (bilateral oophorectomy, hysterectomy or bilateral salpingectomy; tubal ligation alone is not sufficient)
  • Participants who are capable of giving signed , which includes compliance with the requirements (including mandatory intake of rescue medication to participants who have been administered the Plasmodium falciparum sporozoite challenge) and restrictions listed in the informed consent form (ICF) and this protocol
  • Other protocol defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • Participants with 12-Lead (ECG) outside normal range ( greater than [>] 450 milli seconds [ms], pulse rate [PR] > 215 ms, or QRS > 120 ms) and deemed by the Investigator
  • Supine systolic blood pressure > 140 or \< 90 millimeter of mercury (mmHg), diastolic blood pressure > 90 or \< 50 mmHg, and pulse rate > 90 or \< 50 beats per minute (min) at screening and at admission on Day -1 (any abnormal blood pressure or pulse rate results may be repeated once and if the repeat result is within the normal range, it is not considered to have met the exclusion criterion)
  • Seropositive for (HIV) I and II antibody or antigen), virus (HBV; hepatitis B surface antigen [HBsAg]), or virus (HCV; antibody) tests
  • Liver function tests above the (ULN) (> 3 x ULN) the day before DVI / study intervention administration (Day -1)
  • History or presence of diagnosed food or known drug allergies (including but not limited to allergy to any of the antimalarial rescue medications to be used in the study), or history of anaphylaxis or other severe allergic reactions
  • Participant with a whole blood donation or loss of > 450 mL within 60 days before administration of study drug or unwilling to defer blood donations for 6 months
  • Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
39 participants (actual)

Study arms

  • Placebo comparator
    Early liver stage: Pooled Placebo

    Participants received single dose of placebo matched to M5717 capsule on Day 1 after 2 hours of Plasmodium falciparum Sporozoite (PfSPZ) (3200 sporozoites per injection) intravenous (IV) inoculation administration on Day 1.

    Biological: PfSPZ Challenge · Drug: Palcebo

  • Experimental
    Early liver stage: 30 mg M5717

    Participants received single dose of M5717 30 mg capsule on Day 1 after 2 hours of PfSPZ (3200 sporozoites per injection) IV inoculation administration on Day 1.

    Biological: PfSPZ Challenge · Drug: M5717 30 mg

  • Experimental
    Early liver stage: 60 mg M5717

    Participants received single dose of M5717 60 mg capsule on Day 1 after 2 hours of PfSPZ (3200 sporozoites per injection) IV inoculation administration on Day 1.

    Biological: PfSPZ Challenge · Drug: M5717 60 mg

  • Experimental
    Early liver stage: 80 mg M5717

    Participants received single dose of M5717 80 mg capsule on Day 1 after 2 hours of PfSPZ (3200 sporozoites per injection) IV inoculation administration on Day 1.

    Biological: PfSPZ Challenge · Drug: M5717 80 mg

  • Experimental
    Early liver stage: 100 mg M5717

    Participants received single dose of M5717 100 mg capsule on Day 1 after 2 hours of PfSPZ (3200 sporozoites per injection) IV inoculation administration on Day 1.

    Biological: PfSPZ Challenge · Drug: M5717 100 mg

  • Experimental
    Early liver stage: 200 mg M5717

    Participants received single dose of M5717 200 mg capsule on Day 1 after 2 hours of PfSPZ (3200 sporozoites per injection) IV inoculation administration on Day 1.

    Biological: PfSPZ Challenge · Drug: M5717 200 mg

  • Experimental
    Late liver stage: Pooled Placebo

    Participants received single dose of placebo matched to M5717 capsule on Day 5 after 96 hours of PfSPZ (3200 sporozoites per injection) IV inoculation administration on Day 1.

    Biological: PfSPZ Challenge · Drug: Placebo

  • Experimental
    Late liver stage: 60 mg M5717

    Participants received single dose of M5717 60 mg capsule on Day 5 after 96 hours of PfSPZ (3200 sporozoites per injection) IV inoculation administration on Day 1.

    Biological: PfSPZ Challenge · Drug: M5717 60 mg

  • Experimental
    Late liver stage: 100 mg M5717

    Participants received single dose of M5717 100 mg capsule on Day 5 after 96 hours of PfSPZ (3200 sporozoites per injection) IV inoculation administration on Day 1.

    Biological: PfSPZ Challenge · Drug: M5717 100 mg

  • Experimental
    Late liver stage: 200 mg M5717

    Participants received single dose of M5717 200 mg capsule on Day 5 after 96 hours of PfSPZ (3200 sporozoites per injection) IV inoculation administration on Day 1.

    Biological: PfSPZ Challenge · Drug: M5717 200 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Early Liver Stage: Number of Participants Over Time With Positive Parasitemia

    Number of participants with positive parasitemia defined as first positive quantitative polymerase chain reaction (qPCR) outcome equal or greater than 100 asexual parasites per milliliter (mL) of blood within 28 days of PfSPZ challenge.

    Time frame: Early Liver Stage: From Day 1 up to Day 28

  2. Late Liver Stage: Number of Participants Over Time With Positive Parasitemia

    Number of participants with positive parasitemia defined as first positive quantitative polymerase chain reaction (qPCR) outcome equal or greater than 100 asexual parasites per milliliter (mL) of blood within 28 days of PfSPZ challenge.

    Time frame: Late Liver Stage: From Day 5 up to Day 32

  3. Early Liver Stage: Time to First Positive Parasitemia Based on Quantitative Polymerase Chain Reaction (qPCR)

    Time to first positive parasitemia was defined as the time (i.e., number of days) from the PfSPZ DVI (i.e., date of DVI PfSPZ) to the first qPCR outcome greater than or equal to (\>=) 100 asexual parasites per milliliter (mL) of blood.

    Time frame: Early Liver Stage: From Day 1 up to Day 28

  4. Late Liver Stage: Time to First Positive Parasitemia Based on Quantitative Polymerase Chain Reaction (qPCR)

    Time to first positive parasitemia was defined as the time (i.e., number of days) from the PfSPZ DVI (i.e., date of DVI PfSPZ) to the first qPCR outcome greater than or equal to (\>=) 100 asexual parasites per milliliter (mL) of blood.

    Time frame: Late Liver Stage: From Day 5 up to Day 32

  5. Early Liver Stage: Number of Participants With Documented Blood Stage Parasite Growth

    Documented blood stage parasite growth was defined as an increase of qPCR measured asexual parasites per mL compared to the first parasitemia measurement, within 28 days of PfSPZ DVI.

    Time frame: Early Liver Stage: From Day 1 up to Day 28

  6. Late Liver Stage: Number of Participants With Documented Blood Stage Parasite Growth

    Documented blood stage parasite growth was defined as an increase of qPCR measured asexual parasites per mL compared to the first parasitemia measurement, within 28 days of PfSPZ DVI.

    Time frame: Late Liver Stage: From Day 5 up to Day 32

  7. Early Liver Stage: Clinical Symptoms of Malaria Assessed Using Malaria Clinical Score

    The malaria clinical score consisted of 14 signs/symptoms frequently associated with malaria and graded using a 4-point scale (absent: 0; mild: 1; moderate: 2; severe: 3) and summed to generate a total malaria clinical score (maximum score possible is 42): headache, myalgia (muscle ache), arthralgia (joint ache), fatigue/lethargy, malaise (general discomfort/uneasiness), chills/shivering/rigors, sweating/hot spells, anorexia, nausea, vomiting, abdominal discomfort, fever, tachycardia and hypotension. The minimum score was 0 (no symptoms) and the maximum score was 42 (maximum symptoms). Total scores are reported here.

    Time frame: Early Liver Stage: At Day 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 24, 26 and 28

  8. Late Liver Stage: Clinical Symptoms of Malaria Assessed Using Malaria Clinical Score

    The malaria clinical score consisted of 14 signs/symptoms frequently associated with malaria and graded using a 4-point scale (absent: 0; mild: 1; moderate: 2; severe: 3) and summed to generate a total malaria clinical score (maximum score possible is 42): headache, myalgia (muscle ache), arthralgia (joint ache), fatigue/lethargy, malaise (general discomfort/uneasiness), chills/shivering/rigors, sweating/hot spells, anorexia, nausea, vomiting, abdominal discomfort, fever, tachycardia and hypotension. The minimum score was 0 (no symptoms) and the maximum score was 42 (maximum symptoms). Total scores are reported here.

    Time frame: Late Liver Stage: At Day 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30 and 32

  9. Dose Exposure Response Relationship of M5717 Assessed by Logistic Regression Model

    Exposure efficacy relationship was analyzed using logistic regression model. Different exposure matrices (AUC0-24, AUC0-168, AUC0-inf, C24 and C168) were analyzed using logistic regression model.

    Time frame: From Day 5 up to Day 32

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and Treatment-related TEAEs

    An adverse event (AE) was defined as any untoward medical occurrence in a participant administered with study drug which does not necessarily had a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAE was defined as AEs starting or worsening after the first intake of the study drug. TEAEs included both serious TEAEs and non-serious TEAEs. Treatment-related TEAEs: reasonably related to study intervention.

    Time frame: Early Liver Stage: From Day 1 up to Day 33; Late Liver Stage: From Day 1 up to Day 36

  2. Number of Participants With Treatment Emergent Adverse Events (TEAEs) Based on Severity

    Severity of adverse events (AE) were assessed by the investigator per the Qualitative Toxicity Scale. Grade 1= Mild, Grade 2=Moderate, Grade 3=Severe. The number of participants that experienced at least one solicited local TEAE were summarized by grade. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs include both Serious TEAEs and non-serious TEAEs. Number of participants with Grade=1, Grade=2 and 3 were reported.

    Time frame: Early Liver Stage: From Day 1 up to Day 33; Late Liver Stage: From Day 1 up to Day 36

  3. Number of Participants With Clinically Significant Change From Baseline in Laboratory Values

    Laboratory assessments included hematology, biochemistry, urinalysis, and coagulation. Number of participants with clinically significant changes from baseline in laboratory values which were deemed clinically significant by the investigator were reported.

    Time frame: Early Liver Stage: From Day 1 up to Day 33; Late Liver Stage: From Day 1 up to Day 36

  4. Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    Vital signs included oral body temperature, height, weight, systolic blood pressure, diastolic blood pressure, and pulse rate. Number of participants with clinically significant changes from baseline in Vital signs which were deemed clinically significant by the investigator were reported.

    Time frame: Early Liver Stage: From Day 1 up to Day 33; Late Liver Stage: From Day 1 up to Day 36

  5. Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiogram (ECG) Findings

    Single 12-lead ECG was obtained as outlined using an ECG machine that automatically calculates the heart rate and measures PR, QRS, and QT intervals. Number of participants with clinically significant changes from baseline in ECG which were deemed clinically significant by the investigator were reported.

    Time frame: Early Liver Stage: From Day 1 up to Day 33; Late Liver Stage: From Day 1 up to Day 36

  6. Area Under the Blood Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of M5717

    AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated blood concentration at the last sampling time point at which the measured blood concentration is at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured blood concentrations of the terminal log-linear phase.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120, 168, 192, 600, and 768 hours post-dose

  7. Area Under the Blood Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-tlast) of M5717

    Area under the blood concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120, 168, 192, 600, and 768 hours post-dose

  8. Area Under the Blood Concentration-Time Curve From Time Zero to 24 Hours Post-dose (AUC 0-24) of M5717

    AUC from time zero to 24 hours post dose, calculated using the mixed log linear trapezoidal rule (linear up, log down) using the nominal dosing interval.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 6, 12 and 24 hours post-dose

  9. Area Under the Blood Concentration-Time Curve From Time Zero to 168 Hours Post-dose (AUC 0-168) of M5717

    AUC from time zero to 168 hours post dose. Calculated using the mixed log linear trapezoidal rule (linear up, log down) using the nominal dosing interval.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120 and 168 hours post-dose

  10. Maximum Observed Blood Concentration (Cmax) of M5717

    Cmax was obtained directly from the concentration versus time curve.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120, 168, 192, 600, and 768 hours post-dose

  11. Blood Concentration at 24 Hours (C24) of M5717

    Blood samples for PK analysis of C24 of M5717 was reported.

    Time frame: At 24 hours post-dose

  12. Blood Concentration at 168 Hours (C168) of M5717

    C168 is the calculated blood concentration at 168 hours post-dose at which the measured blood concentration is at or above the Lower Limit of quantification (LLQ).

    Time frame: At 168 hours post-dose

  13. Time to Reach Maximum Blood Concentration (Tmax) of M5717

    Time to reach the maximum blood concentration (Tmax) was obtained directly from the concentration versus time curve.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120, 168, 192, 600, and 768 hours post-dose

  14. Apparent Terminal Half-life (t1/2) of M5717

    Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by lambda z.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120, 168, 192, 600, and 768 hours post-dose

  15. Elimination Rate Constant (Lambda z) of M5717

    Elimination rate constant determined from the terminal slope of the log-transformed concentration curve using linear regression on terminal data points of the curve.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120, 168, 192, 600, and 768 hours post-dose

  16. Apparent Total Body Clearance From Blood (CL/f) of M5717

    Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from blood, CL= Dose/AUC0-inf

    Time frame: Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120, 168, 192, 600, and 768 hours post-dose

  17. Apparent Volume of Distribution (Vz/F) During the Terminal Phase of M5717

    The Vz/f was defined as the theoretical volume in which the total amount of required to uniformly distribute to produce the desired plasma concentration. Apparent volume of distribution after oral dose (Vz/F) was influenced by the fraction absorbed. The Vz/f was calculated by dividing the dose with area under the concentration time curve from time zero to infinity multiplied with terminal elimination rate constant Lambda(z). Vz/f=Dose/AUC(0-inf) multiply Lambda(z).

    Time frame: Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120, 168, 192, 600, and 768 hours post-dose

07

Results

Posted May 1, 2024

Participant flow

Participant flow — Overall Study
MilestoneEarly Liver Stage: Pooled PlaceboEarly Liver Stage: 30 mg M5717Early Liver Stage: 60 mg M5717Early Liver Stage: 80 mg M5717Early Liver Stage: 100 mg M5717Early Liver Stage: 200 mg M5717Late Liver Stage: Pooled PlaceboLate Liver Stage: 60 mg M5717Late Liver Stage: 100 mg M5717Late Liver Stage: 200 mg M5717
Started6366333333
Completed6366333333
Not completed0000000000

Outcome measures

PrimaryEarly Liver Stage: Number of Participants Over Time With Positive Parasitemia

Number of participants with positive parasitemia defined as first positive quantitative polymerase chain reaction (qPCR) outcome equal or greater than 100 asexual parasites per milliliter (mL) of blood within 28 days of PfSPZ challenge.

Time frame:
Early Liver Stage: From Day 1 up to Day 28
Reported as:
Count of participants · Participants
Early Liver Stage: Number of Participants Over Time With Positive Parasitemia
ParticipantsEarly Liver Stage: Pooled PlaceboEarly Liver Stage: 30 mg M5717Early Liver Stage: 60 mg M5717Early Liver Stage: 80 mg M5717Early Liver Stage: 100 mg M5717Early Liver Stage: 200 mg M5717
Early Liver Stage: Number of Participants Over Time With Positive Parasitemia632100
PrimaryLate Liver Stage: Number of Participants Over Time With Positive Parasitemia

Number of participants with positive parasitemia defined as first positive quantitative polymerase chain reaction (qPCR) outcome equal or greater than 100 asexual parasites per milliliter (mL) of blood within 28 days of PfSPZ challenge.

Time frame:
Late Liver Stage: From Day 5 up to Day 32
Reported as:
Count of participants · Participants
Late Liver Stage: Number of Participants Over Time With Positive Parasitemia
ParticipantsLate Liver Stage: Pooled PlaceboLate Liver Stage: 60 mg M5717Late Liver Stage: 100 mg M5717Late Liver Stage: 200 mg M5717
Late Liver Stage: Number of Participants Over Time With Positive Parasitemia3000
PrimaryEarly Liver Stage: Time to First Positive Parasitemia Based on Quantitative Polymerase Chain Reaction (qPCR)

Time to first positive parasitemia was defined as the time (i.e., number of days) from the PfSPZ DVI (i.e., date of DVI PfSPZ) to the first qPCR outcome greater than or equal to (\>=) 100 asexual parasites per milliliter (mL) of blood.

Time frame:
Early Liver Stage: From Day 1 up to Day 28
Reported as:
Median · Days
Early Liver Stage: Time to First Positive Parasitemia Based on Quantitative Polymerase Chain Reaction (qPCR)
DaysEarly Liver Stage: Pooled PlaceboEarly Liver Stage: 30 mg M5717Early Liver Stage: 60 mg M5717Early Liver Stage: 80 mg M5717Early Liver Stage: 100 mg M5717Early Liver Stage: 200 mg M5717
Early Liver Stage: Time to First Positive Parasitemia Based on Quantitative Polymerase Chain Reaction (qPCR)10.0 (9 to 12)15.0 (15 to 18)22.0 (20 to 24)24.0 (24 to 24)——
PrimaryLate Liver Stage: Time to First Positive Parasitemia Based on Quantitative Polymerase Chain Reaction (qPCR)

Time to first positive parasitemia was defined as the time (i.e., number of days) from the PfSPZ DVI (i.e., date of DVI PfSPZ) to the first qPCR outcome greater than or equal to (\>=) 100 asexual parasites per milliliter (mL) of blood.

Time frame:
Late Liver Stage: From Day 5 up to Day 32
Reported as:
Median · Days
Late Liver Stage: Time to First Positive Parasitemia Based on Quantitative Polymerase Chain Reaction (qPCR)
DaysLate Liver Stage: Pooled PlaceboLate Liver Stage: 60 mg M5717Late Liver Stage: 100 mg M5717Late Liver Stage: 200 mg M5717
Late Liver Stage: Time to First Positive Parasitemia Based on Quantitative Polymerase Chain Reaction (qPCR)10.0 (9 to 11)———
PrimaryEarly Liver Stage: Number of Participants With Documented Blood Stage Parasite Growth

Documented blood stage parasite growth was defined as an increase of qPCR measured asexual parasites per mL compared to the first parasitemia measurement, within 28 days of PfSPZ DVI.

Time frame:
Early Liver Stage: From Day 1 up to Day 28
Reported as:
Count of participants · Participants
Early Liver Stage: Number of Participants With Documented Blood Stage Parasite Growth
ParticipantsEarly Liver Stage: Pooled PlaceboEarly Liver Stage: 30 mg M5717Early Liver Stage: 60 mg M5717Early Liver Stage: 80 mg M5717Early Liver Stage: 100 mg M5717Early Liver Stage: 200 mg M5717
Early Liver Stage: Number of Participants With Documented Blood Stage Parasite Growth522100
PrimaryLate Liver Stage: Number of Participants With Documented Blood Stage Parasite Growth

Documented blood stage parasite growth was defined as an increase of qPCR measured asexual parasites per mL compared to the first parasitemia measurement, within 28 days of PfSPZ DVI.

Time frame:
Late Liver Stage: From Day 5 up to Day 32
Reported as:
Count of participants · Participants
Late Liver Stage: Number of Participants With Documented Blood Stage Parasite Growth
ParticipantsLate Liver Stage: Pooled PlaceboLate Liver Stage: 60 mg M5717Late Liver Stage: 100 mg M5717Late Liver Stage: 200 mg M5717
Late Liver Stage: Number of Participants With Documented Blood Stage Parasite Growth3000
PrimaryEarly Liver Stage: Clinical Symptoms of Malaria Assessed Using Malaria Clinical Score

The malaria clinical score consisted of 14 signs/symptoms frequently associated with malaria and graded using a 4-point scale (absent: 0; mild: 1; moderate: 2; severe: 3) and summed to generate a total malaria clinical score (maximum score possible is 42): headache, myalgia (muscle ache), arthralgia (joint ache), fatigue/lethargy, malaise (general discomfort/uneasiness), chills/shivering/rigors, sweating/hot spells, anorexia, nausea, vomiting, abdominal discomfort, fever, tachycardia and hypotension. The minimum score was 0 (no symptoms) and the maximum score was 42 (maximum symptoms). Total scores are reported here.

Time frame:
Early Liver Stage: At Day 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 24, 26 and 28
Reported as:
Mean · score on a Scale
Early Liver Stage: Clinical Symptoms of Malaria Assessed Using Malaria Clinical Score
score on a ScaleEarly Liver Stage: Pooled PlaceboEarly Liver Stage: 30 mg M5717Early Liver Stage: 60 mg M5717Early Liver Stage: 80 mg M5717Early Liver Stage: 100 mg M5717Early Liver Stage: 200 mg M5717
At Day 60.0 ± 0.000.3 ± 0.580.2 ± 0.410.0 ± 0.000.0 ± 0.000.1 ± 0.30
At Day 70.3 ± 0.520.3 ± 0.580.0 ± 0.000.0 ± 0.000.0 ± 0.000.0 ± 0.00
At Day 80.2 ± 0.410.3 ± 0.580.0 ± 0.000.0 ± 0.000.0 ± 0.000.0 ± 0.00
At Day 90.2 ± 0.410.3 ± 0.580.2 ± 0.410.0 ± 0.000.0 ± 0.000.0 ± 0.00
At Day 100.3 ± 0.520.3 ± 0.580.0 ± 0.000.3 ± 0.520.0 ± 0.000.0 ± 0.00
At Day 110.2 ± 0.410.0 ± 0.000.0 ± 0.000.2 ± 0.410.0 ± 0.000.0 ± 0.00
At Day 120.0 ± 0.000.0 ± 0.000.0 ± 0.000.2 ± 0.410.0 ± 0.000.0 ± 0.00
At Day 131.7 ± 1.860.0 ± 0.000.0 ± 0.000.0 ± 0.000.0 ± 0.000.0 ± 0.00
At Day 144.5 ± 3.000.0 ± 0.000.0 ± 0.000.0 ± 0.000.0 ± 0.000.0 ± 0.00
At Day 151.5 ± 2.070.0 ± 0.000.2 ± 0.410.2 ± 0.410.0 ± 0.000.0 ± 0.00
At Day 162.0 ± 1.410.3 ± 0.580.3 ± 0.520.2 ± 0.410.0 ± 0.000.0 ± 0.00
At Day 170.5 ± 0.712.0 ± 3.460.3 ± 0.520.2 ± 0.410.0 ± 0.000.0 ± 0.00
At Day 181.0 ± 1.412.3 ± 4.040.3 ± 0.520.2 ± 0.410.3 ± 0.580.3 ± 0.58
At Day 19—0.7 ± 1.150.3 ± 0.520.0 ± 0.000.3 ± 0.580.0 ± 0.00
At Day 20—1.0 ± 1.730.0 ± 0.000.0 ± 0.000.3 ± 0.580.0 ± 0.00
At Day 220.0 ± 0.000.7 ± 1.150.0 ± 0.000.2 ± 0.410.0 ± 0.000.0 ± 0.00
At Day 24——0.0 ± 0.000.2 ± 0.410.0 ± 0.000.0 ± 0.00
At Day 260.0 ± 0.000.0 ± 0.000.2 ± 0.410.2 ± 0.410.0 ± 0.000.3 ± 0.58
At Day 280.0 ± 0.00.0 ± 0.000.2 ± 0.410.2 ± 0.410.3 ± 0.580.0 ± 0.00
PrimaryLate Liver Stage: Clinical Symptoms of Malaria Assessed Using Malaria Clinical Score

The malaria clinical score consisted of 14 signs/symptoms frequently associated with malaria and graded using a 4-point scale (absent: 0; mild: 1; moderate: 2; severe: 3) and summed to generate a total malaria clinical score (maximum score possible is 42): headache, myalgia (muscle ache), arthralgia (joint ache), fatigue/lethargy, malaise (general discomfort/uneasiness), chills/shivering/rigors, sweating/hot spells, anorexia, nausea, vomiting, abdominal discomfort, fever, tachycardia and hypotension. The minimum score was 0 (no symptoms) and the maximum score was 42 (maximum symptoms). Total scores are reported here.

Time frame:
Late Liver Stage: At Day 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30 and 32
Reported as:
Mean · Score on a Scale
Late Liver Stage: Clinical Symptoms of Malaria Assessed Using Malaria Clinical Score
Score on a ScaleLate Liver Stage: Pooled PlaceboLate Liver Stage: 60 mg M5717Late Liver Stage: 100 mg M5717Late Liver Stage: 200 mg M5717
At Day 60.0 ± 0.000.0 ± 0.000.0 ± 0.000.0 ± 0.00
At Day 70.0 ± 0.000.3 ± 0.580.0 ± 0.000.0 ± 0.00
At Day 80.0 ± 0.000.0 ± 0.000.3 ± 0.580.0 ± 0.00
At Day 90.3 ± 0.580.0 ± 0.000.3 ± 0.580.0 ± 0.00
At Day 100.3 ± 0.580.0 ± 0.000.0 ± 0.000.0 ± 0.00
At Day 110.0 ± 0.000.0 ± 0.000.0 ± 0.000.0 ± 0.00
At Day 120.0 ± 0.000.0 ± 0.000.0 ± 0.000.0 ± 0.00
At Day 130.0 ± 0.000.3 ± 0.580.0 ± 0.000.0 ± 0.00
At Day 140.0 ± 0.000.0 ± 0.000.3 ± 0.580.0 ± 0.00
At Day 151.5 ± 2.120.0 ± 0.000.3 ± 0.580.3 ± 0.58
At Day 161.5 ± 2.120.3 ± 0.580.0 ± 0.000.0 ± 0.00
At Day 171.00.0 ± 0.000.3 ± 0.580.7 ± 1.15
At Day 18—0.3 ± 0.580.3 ± 0.580.0 ± 0.00
At Day 190.0 ± 0.000.0 ± 0.000.3 ± 0.580.0 ± 0.00
At Day 20—0.0 ± 0.000.3 ± 0.580.0 ± 0.00
At Day 21—0.3 ± 0.580.3 ± 0.580.3 ± 0.58
At Day 22—0.0 ± 0.000.3 ± 0.580.3 ± 0.58
At Day 23—0.0 ± 0.000.0 ± 0.000.3 ± 0.58
At Day 24—0.0 ± 0.000.0 ± 0.000.0 ± 0.00
At Day 260.3 ± 0.580.3 ± 0.580.0 ± 0.000.0 ± 0.00
At Day 28—0.0 ± 0.000.0 ± 0.000.0 ± 0.00
At Day 300.0 ± 0.000.0 ± 0.000.0 ± 0.000.00 ± 0.00
At Day 320.0 ± 0.000.0 ± 0.000.0 ± 0.000.0 ± 0.00
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and Treatment-related TEAEs

An adverse event (AE) was defined as any untoward medical occurrence in a participant administered with study drug which does not necessarily had a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAE was defined as AEs starting or worsening after the first intake of the study drug. TEAEs included both serious TEAEs and non-serious TEAEs. Treatment-related TEAEs: reasonably related to study intervention.

Time frame:
Early Liver Stage: From Day 1 up to Day 33; Late Liver Stage: From Day 1 up to Day 36
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and Treatment-related TEAEs
ParticipantsEarly Liver Stage: Pooled PlaceboEarly Liver Stage: 30 mg M5717Early Liver Stage: 60 mg M5717Early Liver Stage: 80 mg M5717Early Liver Stage: 100 mg M5717Early Liver Stage: 200 mg M5717Late Liver Stage: Pooled PlaceboLate Liver Stage: 60 mg M5717Late Liver Stage: 100 mg M5717Late Liver Stage: 200 mg M5717
Participants with TEAEs5366333322
Participants with Serious TEAEs0000000000
Participants with Treatment-related TEAEs2022130100
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) Based on Severity

Severity of adverse events (AE) were assessed by the investigator per the Qualitative Toxicity Scale. Grade 1= Mild, Grade 2=Moderate, Grade 3=Severe. The number of participants that experienced at least one solicited local TEAE were summarized by grade. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs include both Serious TEAEs and non-serious TEAEs. Number of participants with Grade=1, Grade=2 and 3 were reported.

Time frame:
Early Liver Stage: From Day 1 up to Day 33; Late Liver Stage: From Day 1 up to Day 36
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Based on Severity
ParticipantsEarly Liver Stage: Pooled PlaceboEarly Liver Stage: 30 mg M5717Early Liver Stage: 60 mg M5717Early Liver Stage: 80 mg M5717Early Liver Stage: 100 mg M5717Early Liver Stage: 200 mg M5717Late Liver Stage: Pooled PlaceboLate Liver Stage: 60 mg M5717Late Liver Stage: 100 mg M5717Late Liver Stage: 200 mg M5717
Grade 1 (Mild)5366333322
Grade 2 (Moderate)3221012000
Grade 3 (Severe)0000100010
SecondaryNumber of Participants With Clinically Significant Change From Baseline in Laboratory Values

Laboratory assessments included hematology, biochemistry, urinalysis, and coagulation. Number of participants with clinically significant changes from baseline in laboratory values which were deemed clinically significant by the investigator were reported.

Time frame:
Early Liver Stage: From Day 1 up to Day 33; Late Liver Stage: From Day 1 up to Day 36
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Laboratory Values
ParticipantsEarly Liver Stage: Pooled PlaceboEarly Liver Stage: 30 mg M5717Early Liver Stage: 60 mg M5717Early Liver Stage: 80 mg M5717Early Liver Stage: 100 mg M5717Early Liver Stage: 200 mg M5717Late Liver Stage: Pooled PlaceboLate Liver Stage: 60 mg M5717Late Liver Stage: 100 mg M5717Late Liver Stage: 200 mg M5717
Number of Participants With Clinically Significant Change From Baseline in Laboratory Values0000000000
SecondaryNumber of Participants With Clinically Significant Change From Baseline in Vital Signs

Vital signs included oral body temperature, height, weight, systolic blood pressure, diastolic blood pressure, and pulse rate. Number of participants with clinically significant changes from baseline in Vital signs which were deemed clinically significant by the investigator were reported.

Time frame:
Early Liver Stage: From Day 1 up to Day 33; Late Liver Stage: From Day 1 up to Day 36
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
ParticipantsEarly Liver Stage: Pooled PlaceboEarly Liver Stage: 30 mg M5717Early Liver Stage: 60 mg M5717Early Liver Stage: 80 mg M5717Early Liver Stage: 100 mg M5717Early Liver Stage: 200 mg M5717Late Liver Stage: Pooled PlaceboLate Liver Stage: 60 mg M5717Late Liver Stage: 100 mg M5717Late Liver Stage: 200 mg M5717
Number of Participants With Clinically Significant Change From Baseline in Vital Signs0000000000
SecondaryNumber of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiogram (ECG) Findings

Single 12-lead ECG was obtained as outlined using an ECG machine that automatically calculates the heart rate and measures PR, QRS, and QT intervals. Number of participants with clinically significant changes from baseline in ECG which were deemed clinically significant by the investigator were reported.

Time frame:
Early Liver Stage: From Day 1 up to Day 33; Late Liver Stage: From Day 1 up to Day 36
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiogram (ECG) Findings
ParticipantsEarly Liver Stage: Pooled PlaceboEarly Liver Stage: 30 mg M5717Early Liver Stage: 60 mg M5717Early Liver Stage: 80 mg M5717Early Liver Stage: 100 mg M5717Early Liver Stage: 200 mg M5717Late Liver Stage: Pooled PlaceboLate Liver Stage: 60 mg M5717Late Liver Stage: 100 mg M5717Late Liver Stage: 200 mg M5717
Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiogram (ECG) Findings0000000000
SecondaryArea Under the Blood Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of M5717

AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated blood concentration at the last sampling time point at which the measured blood concentration is at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured blood concentrations of the terminal log-linear phase.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120, 168, 192, 600, and 768 hours post-dose
Reported as:
Geometric mean · hour*nanogram per milliliter(hour*ng/mL)
Area Under the Blood Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of M5717
hour*nanogram per milliliter(hour*ng/mL)Early Liver Stage: 30 mg M5717Early Liver Stage: 60 mg M5717Early Liver Stage: 80 mg M5717Early Liver Stage: 100 mg M5717Early Liver Stage: 200 mg M5717Late Liver Stage: 60 mg M5717Late Liver Stage: 100 mg M5717Late Liver Stage: 200 mg M5717
Area Under the Blood Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of M5717—1280 ± 31.811990 ± 25.241890 ± 12.529840 ± 37.441100 ± 71.032330 ± 4.704830 ± 53.73
SecondaryArea Under the Blood Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-tlast) of M5717

Area under the blood concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120, 168, 192, 600, and 768 hours post-dose
Reported as:
Geometric mean · hour*ng/mL
Area Under the Blood Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-tlast) of M5717
hour*ng/mLEarly Liver Stage: 30 mg M5717Early Liver Stage: 60 mg M5717Early Liver Stage: 80 mg M5717Early Liver Stage: 100 mg M5717Early Liver Stage: 200 mg M5717Late Liver Stage: 60 mg M5717Late Liver Stage: 100 mg M5717Late Liver Stage: 200 mg M5717
Area Under the Blood Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-tlast) of M571721.9 ± 1160.32852 ± 36.351270 ± 14.081470 ± 4.657330 ± 42.80657 ± 67.171810 ± 8.093820 ± 70.38
SecondaryArea Under the Blood Concentration-Time Curve From Time Zero to 24 Hours Post-dose (AUC 0-24) of M5717

AUC from time zero to 24 hours post dose, calculated using the mixed log linear trapezoidal rule (linear up, log down) using the nominal dosing interval.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 6, 12 and 24 hours post-dose
Reported as:
Geometric mean · h*ng/mL
Area Under the Blood Concentration-Time Curve From Time Zero to 24 Hours Post-dose (AUC 0-24) of M5717
h*ng/mLEarly Liver Stage: 30 mg M5717Early Liver Stage: 60 mg M5717Early Liver Stage: 80 mg M5717Early Liver Stage: 100 mg M5717Early Liver Stage: 200 mg M5717Late Liver Stage: 60 mg M5717Late Liver Stage: 100 mg M5717Late Liver Stage: 200 mg M5717
Area Under the Blood Concentration-Time Curve From Time Zero to 24 Hours Post-dose (AUC 0-24) of M571725.8 ± 639.59198 ± 40.21280 ± 18.23290 ± 39.80975 ± 33.02160 ± 44.63445 ± 8.601020 ± 45.85
SecondaryArea Under the Blood Concentration-Time Curve From Time Zero to 168 Hours Post-dose (AUC 0-168) of M5717

AUC from time zero to 168 hours post dose. Calculated using the mixed log linear trapezoidal rule (linear up, log down) using the nominal dosing interval.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120 and 168 hours post-dose
Reported as:
Geometric mean · h*ng/mL
Area Under the Blood Concentration-Time Curve From Time Zero to 168 Hours Post-dose (AUC 0-168) of M5717
h*ng/mLEarly Liver Stage: 30 mg M5717Early Liver Stage: 60 mg M5717Early Liver Stage: 80 mg M5717Early Liver Stage: 100 mg M5717Early Liver Stage: 200 mg M5717Late Liver Stage: 60 mg M5717Late Liver Stage: 100 mg M5717Late Liver Stage: 200 mg M5717
Area Under the Blood Concentration-Time Curve From Time Zero to 168 Hours Post-dose (AUC 0-168) of M571750.4 ± 2325.31805 ± 35.221190 ± 14.351390 ± 5.343680 ± 29.33692 ± 53.241710 ± 8.673190 ± 43.40
SecondaryMaximum Observed Blood Concentration (Cmax) of M5717

Cmax was obtained directly from the concentration versus time curve.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120, 168, 192, 600, and 768 hours post-dose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Maximum Observed Blood Concentration (Cmax) of M5717
nanogram per milliliter (ng/mL)Early Liver Stage: 30 mg M5717Early Liver Stage: 60 mg M5717Early Liver Stage: 80 mg M5717Early Liver Stage: 100 mg M5717Early Liver Stage: 200 mg M5717Late Liver Stage: 60 mg M5717Late Liver Stage: 100 mg M5717Late Liver Stage: 200 mg M5717
Maximum Observed Blood Concentration (Cmax) of M57173.56 ± 39.9011.7 ± 36.9316.6 ± 33.7017.2 ± 44.1257.2 ± 38.089.38 ± 82.5027.6 ± 22.1964.4 ± 46.26
SecondaryBlood Concentration at 24 Hours (C24) of M5717

Blood samples for PK analysis of C24 of M5717 was reported.

Time frame:
At 24 hours post-dose
Reported as:
Geometric mean · ng/mL
Blood Concentration at 24 Hours (C24) of M5717
ng/mLEarly Liver Stage: 30 mg M5717Early Liver Stage: 60 mg M5717Early Liver Stage: 80 mg M5717Early Liver Stage: 100 mg M5717Early Liver Stage: 200 mg M5717Late Liver Stage: 60 mg M5717Late Liver Stage: 100 mg M5717Late Liver Stage: 200 mg M5717
Blood Concentration at 24 Hours (C24) of M5717NA ± NA6.77 ± 45.359.42 ± 28.1211.3 ± 31.4230.6 ± 24.916.06 ± 37.8914.9 ± 14.5626.7 ± 37.88
SecondaryBlood Concentration at 168 Hours (C168) of M5717

C168 is the calculated blood concentration at 168 hours post-dose at which the measured blood concentration is at or above the Lower Limit of quantification (LLQ).

Time frame:
At 168 hours post-dose
Reported as:
Geometric mean · ng/mL
Blood Concentration at 168 Hours (C168) of M5717
ng/mLEarly Liver Stage: 30 mg M5717Early Liver Stage: 60 mg M5717Early Liver Stage: 80 mg M5717Early Liver Stage: 100 mg M5717Early Liver Stage: 200 mg M5717Late Liver Stage: 60 mg M5717Late Liver Stage: 100 mg M5717Late Liver Stage: 200 mg M5717
Blood Concentration at 168 Hours (C168) of M5717NA ± NA2.89 ± 38.614.31 ± 13.434.16 ± 24.6011.4 ± 40.64NA ± NA4.88 ± 2.508.30 ± 45.60
SecondaryTime to Reach Maximum Blood Concentration (Tmax) of M5717

Time to reach the maximum blood concentration (Tmax) was obtained directly from the concentration versus time curve.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120, 168, 192, 600, and 768 hours post-dose
Reported as:
Median · Hours
Time to Reach Maximum Blood Concentration (Tmax) of M5717
HoursEarly Liver Stage: 30 mg M5717Early Liver Stage: 60 mg M5717Early Liver Stage: 80 mg M5717Early Liver Stage: 100 mg M5717Early Liver Stage: 200 mg M5717Late Liver Stage: 60 mg M5717Late Liver Stage: 100 mg M5717Late Liver Stage: 200 mg M5717
Time to Reach Maximum Blood Concentration (Tmax) of M57176.00 (0.500 to 12.0)1.00 (0.500 to 12.0)3.25 (0.500 to 12.0)6.00 (0.500 to 12.0)1.00 (0.500 to 6.00)1.00 (0.500 to 1.00)2.00 (1.00 to 2.02)2.00 (2.00 to 2.00)
SecondaryApparent Terminal Half-life (t1/2) of M5717

Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by lambda z.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120, 168, 192, 600, and 768 hours post-dose
Reported as:
Median · Hours
Apparent Terminal Half-life (t1/2) of M5717
HoursEarly Liver Stage: 30 mg M5717Early Liver Stage: 60 mg M5717Early Liver Stage: 80 mg M5717Early Liver Stage: 100 mg M5717Early Liver Stage: 200 mg M5717Late Liver Stage: 60 mg M5717Late Liver Stage: 100 mg M5717Late Liver Stage: 200 mg M5717
Apparent Terminal Half-life (t1/2) of M5717—121 (82.3 to 143)121 (97.2 to 221)66.9 (66.6 to 108)494 (212 to 531)94.1 (74.2 to 156)95.4 (76.0 to 95.5)136 (101 to 183)
SecondaryElimination Rate Constant (Lambda z) of M5717

Elimination rate constant determined from the terminal slope of the log-transformed concentration curve using linear regression on terminal data points of the curve.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120, 168, 192, 600, and 768 hours post-dose
Reported as:
Geometric mean · One per Hours (1/h)
Elimination Rate Constant (Lambda z) of M5717
One per Hours (1/h)Early Liver Stage: 30 mg M5717Early Liver Stage: 60 mg M5717Early Liver Stage: 80 mg M5717Early Liver Stage: 100 mg M5717Early Liver Stage: 200 mg M5717Late Liver Stage: 60 mg M5717Late Liver Stage: 100 mg M5717Late Liver Stage: 200 mg M5717
Elimination Rate Constant (Lambda z) of M5717—0.00597 ± 22.930.00529 ± 30.440.00885 ± 28.590.00182 ± 55.450.00677 ± 38.430.00786 ± 12.780.00511 ± 30.50
SecondaryApparent Total Body Clearance From Blood (CL/f) of M5717

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from blood, CL= Dose/AUC0-inf

Time frame:
Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120, 168, 192, 600, and 768 hours post-dose
Reported as:
Geometric mean · Liter per Hours (L/h)
Apparent Total Body Clearance From Blood (CL/f) of M5717
Liter per Hours (L/h)Early Liver Stage: 30 mg M5717Early Liver Stage: 60 mg M5717Early Liver Stage: 80 mg M5717Early Liver Stage: 100 mg M5717Early Liver Stage: 200 mg M5717Late Liver Stage: 60 mg M5717Late Liver Stage: 100 mg M5717Late Liver Stage: 200 mg M5717
Apparent Total Body Clearance From Blood (CL/f) of M5717—46.9 ± 31.8140.3 ± 25.2452.9 ± 12.5220.3 ± 37.4454.8 ± 71.0343.0 ± 4.7041.4 ± 53.73
SecondaryApparent Volume of Distribution (Vz/F) During the Terminal Phase of M5717

The Vz/f was defined as the theoretical volume in which the total amount of required to uniformly distribute to produce the desired plasma concentration. Apparent volume of distribution after oral dose (Vz/F) was influenced by the fraction absorbed. The Vz/f was calculated by dividing the dose with area under the concentration time curve from time zero to infinity multiplied with terminal elimination rate constant Lambda(z). Vz/f=Dose/AUC(0-inf) multiply Lambda(z).

Time frame:
Pre-dose, 0.5, 1, 2, 3, 6, 12, 24, 120, 168, 192, 600, and 768 hours post-dose
Reported as:
Geometric mean · Liter
Apparent Volume of Distribution (Vz/F) During the Terminal Phase of M5717
LiterEarly Liver Stage: 30 mg M5717Early Liver Stage: 60 mg M5717Early Liver Stage: 80 mg M5717Early Liver Stage: 100 mg M5717Early Liver Stage: 200 mg M5717Late Liver Stage: 60 mg M5717Late Liver Stage: 100 mg M5717Late Liver Stage: 200 mg M5717
Apparent Volume of Distribution (Vz/F) During the Terminal Phase of M5717—7850 ± 42.717600 ± 10.875980 ± 15.5711200 ± 60.478130 ± 35.295490 ± 15.7127.59 ± 8340
PrimaryDose Exposure Response Relationship of M5717 Assessed by Logistic Regression Model

Exposure efficacy relationship was analyzed using logistic regression model. Different exposure matrices (AUC0-24, AUC0-168, AUC0-inf, C24 and C168) were analyzed using logistic regression model.

Time frame:
From Day 5 up to Day 32
Reported as:
Number · slope
Dose Exposure Response Relationship of M5717 Assessed by Logistic Regression Model
slopeAll Participants: AUC0-24All Participants: AUC0-168All Participants: AUC0-infAll Participants: C24All Participants: C168
Dose Exposure Response Relationship of M5717 Assessed by Logistic Regression Model1.271.431.440.8002.45
Statistical analysis
  • All Participants: AUC0-24 · Regression, Logistic · p = 0.00284 · Odds ratio (or): 3.57 · 95% CI 1.85 to 10.6
  • All Participants: AUC0-168 · Regression, Logistic · p = 0.00367 · Odds ratio (or): 4.19 · 95% CI 2.00 to 14.8
  • All Participants: AUC0-inf · Regression, Logistic · p = 0.0137 · Odds ratio (or): 4.22 · 95% CI 1.90 to 23.7
  • All Participants: C24 · Regression, Logistic · p = 0.00349 · Odds ratio (or): 2.23 · 95% CI 1.47 to 4.48
  • All Participants: C168 · Regression, Logistic · p = 0.00594 · Odds ratio (or): 11.6 · 95% CI 3.19 to 129

Adverse events

Collected over Early Liver Stage: From Day 1 up to Day 33; Late Liver Stage: From Day 1 up to Day 36. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Early Liver Stage: Pooled Placebo0/6 (0%)0/6 (0%)5/6 (83.3%)
Early Liver Stage: 30 mg M57170/3 (0%)0/3 (0%)3/3 (100%)
Early Liver Stage: 60 mg M57170/6 (0%)0/6 (0%)6/6 (100%)
Early Liver Stage: 80 mg M57170/6 (0%)0/6 (0%)6/6 (100%)
Early Liver Stage: 100 mg M57170/3 (0%)0/3 (0%)3/3 (100%)
Early Liver Stage: 200 mg M57170/3 (0%)0/3 (0%)3/3 (100%)
Late Liver Stage: Pooled Placebo0/3 (0%)0/3 (0%)3/3 (100%)
Late Liver Stage: 60 mg M57170/3 (0%)0/3 (0%)3/3 (100%)
Late Liver Stage: 100 mg M57170/3 (0%)0/3 (0%)2/3 (66.7%)
Late Liver Stage: 200 mg M57170/3 (0%)0/3 (0%)2/3 (66.7%)
Most frequent other events
Showing 10 of 20
Most frequent other events
EventEarly Liver Stage: Pooled PlaceboEarly Liver Stage: 30 mg M5717Early Liver Stage: 60 mg M5717Early Liver Stage: 80 mg M5717Early Liver Stage: 100 mg M5717Early Liver Stage: 200 mg M5717Late Liver Stage: Pooled PlaceboLate Liver Stage: 60 mg M5717Late Liver Stage: 100 mg M5717Late Liver Stage: 200 mg M5717
DiarrhoeaGastrointestinal disorders2/60/31/62/63/32/32/31/31/30/3
NauseaGastrointestinal disorders4/60/34/61/62/31/33/32/31/32/3
MyalgiaMusculoskeletal and connective tissue disorders3/63/34/63/61/31/30/32/31/31/3
FatigueGeneral disorders3/62/31/60/61/30/31/33/30/31/3
HeadacheNervous system disorders4/62/33/63/62/32/32/30/31/31/3
DizzinessNervous system disorders3/60/31/60/60/30/30/30/31/30/3
Abdominal discomfortGastrointestinal disorders2/60/31/61/60/30/31/30/31/30/3
Abdominal distensionGastrointestinal disorders1/61/30/60/61/31/30/31/30/30/3
Abdominal painGastrointestinal disorders0/60/30/61/60/30/31/30/30/30/3
VomitingGastrointestinal disorders1/60/30/60/61/30/30/30/30/30/3

Baseline characteristics

Safety analysis population (SAF) included all intent to treat (ITT) participants, who have been inoculated using a Direct Intravenous Inoculation (DVI) of PfSPZ and who were administered one dose of study intervention (M5717 or placebo). ITT population included all participants, who were randomized to study intervention.

Age, Categorical
Age, Categorical(Participants)Early Liver Stage: Pooled PlaceboEarly Liver Stage: 30 mg M5717Early Liver Stage: 60 mg M5717Early Liver Stage: 80 mg M5717Early Liver Stage: 100 mg M5717Early Liver Stage: 200 mg M5717Late Liver Stage: Pooled PlaceboLate Liver Stage: 60 mg M5717Late Liver Stage: 100 mg M5717Late Liver Stage: 200 mg M5717Total
<=18 years00000000000
Between 18 and 65 years636633333339
>=65 years00000000000
Sex: Female, Male
Sex: Female, Male(Participants)Early Liver Stage: Pooled PlaceboEarly Liver Stage: 30 mg M5717Early Liver Stage: 60 mg M5717Early Liver Stage: 80 mg M5717Early Liver Stage: 100 mg M5717Early Liver Stage: 200 mg M5717Late Liver Stage: Pooled PlaceboLate Liver Stage: 60 mg M5717Late Liver Stage: 100 mg M5717Late Liver Stage: 200 mg M5717Total
Female002300212111
Male634333121228
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Early Liver Stage: Pooled PlaceboEarly Liver Stage: 30 mg M5717Early Liver Stage: 60 mg M5717Early Liver Stage: 80 mg M5717Early Liver Stage: 100 mg M5717Early Liver Stage: 200 mg M5717Late Liver Stage: Pooled PlaceboLate Liver Stage: 60 mg M5717Late Liver Stage: 100 mg M5717Late Liver Stage: 200 mg M5717Total
Hispanic or Latino00000000000
Not Hispanic or Latino635633333338
Unknown or Not Reported00100000001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Early Liver Stage: Pooled PlaceboEarly Liver Stage: 30 mg M5717Early Liver Stage: 60 mg M5717Early Liver Stage: 80 mg M5717Early Liver Stage: 100 mg M5717Early Liver Stage: 200 mg M5717Late Liver Stage: Pooled PlaceboLate Liver Stage: 60 mg M5717Late Liver Stage: 100 mg M5717Late Liver Stage: 200 mg M5717Total
American Indian or Alaska Native00000000000
Asian10000000001
Native Hawaiian or Other Pacific Islander00000000000
Black or African American00000101002
White536532323335
More than one race00010000001
Unknown or Not Reported00000000000
08

Study locations

1 site
  • Leiden University Medical Center
    Leiden, Netherlands
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and the European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in Aug 2021, 18 months.

Results were first posted in May 2024, 2 years 8 months after primary completion.

Of 29 industry-sponsored phase 1 interventional studies under Malaria, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 18. This study's 18 months is above that.

Counting every sponsor, half of 93 studies reached it within 13 months; a quarter within 7 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2020
First posted
Jan 31, 2020
StartActual
Feb 17, 2020
Primary completionActual
Aug 18, 2021
CompletionActual
Aug 18, 2021
Results first posted
May 1, 2024
Last update
May 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04250363
Responsible party
Sponsor
First posted
Jan 31, 2020
Start date
Feb 17, 2020
Primary completion
Aug 18, 2021
Completion
Aug 18, 2021
Results posted
May 1, 2024
Last update
May 1, 2024

Study contacts

Medical Responsible
study director · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabamiquine

Start the discussion